Nerve growth factor and neuropeptides circulating levels in systemic sclerosis (scleroderma)

M. Matucci-Cerinic, R. Giacomelli, A. Pignone, M. Cagnoni, S. Generini, R. Casale, P. Cipriani, A. Del Rosso, P. Tirassa, Y. T. Konttinen, B. M. Kahaleh, P. S. Fan, M. Paoletti, C. Marchesi, L. Aloe, M. L. Cagnoni

Research output: Contribution to journalArticlepeer-review


Objective - To determine the circulating levels of nerve growth factor (NGF), neuropeptide Y (NPY), and vasoactive intestinal peptide (VIP) in systemic sclerosis (SSc), and to correlate these levels with clinical and laboratory features. Methods - Forty four patients with SSc were evaluated for circulating NGF (immunoenzymatic assay), NPY and VIP (radioimmunoassay), anticentromere and antitopoisomerase I autoantibodies, lung disease (pulmonary function tests with carbon monoxide transfer factor (TLCO), ventilation scintiscan with 99mTc DTPA radioaerosol, high resolution computed tomography (HRCT), pulmonary pressure (echo colour Doppler)), heart disease (standard and 24 ECG, echocardiography), cutaneous involvement (skin score), joint involvement (evidence of tender or swollen joints, or both), peripheral nervous system (PNS) involvement (electromyography), rheumatoid factor, angiotensin converting enzyme (fluorimetric method), von Willebrand factor (ELISA), and erythrocyte sedimentation rate (ESR) (Westergren). Results - Circulating NGF levels in SSc were significantly increased compared with controls (p

Original languageEnglish
Pages (from-to)487-494
Number of pages8
JournalAnnals of the Rheumatic Diseases
Issue number5
Publication statusPublished - 2001

ASJC Scopus subject areas

  • Rheumatology
  • Immunology


Dive into the research topics of 'Nerve growth factor and neuropeptides circulating levels in systemic sclerosis (scleroderma)'. Together they form a unique fingerprint.

Cite this